1. Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial 
Catriona Parker, PhD, Shekhar Krishnan, FRCPath, Lina Hamadeh, PhD, Prof Julie A E Irving, PhD, Prof Roland P Kuiper, PhD, Prof Tamas Révész, FRACP, Prof Peter Hoogerbrugge, MD, Jeremy Hancock, PhD, Rosemary Sutton, PhD, Prof Anthony V Moorman, PhD, Prof Vaskar Saha, FRCPCH 
The Lancet Haematology 
Volume 6, Issue 4, Pages e204-e216 (April 2019)
DOI: /S (19)
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions

2. Figure 1
Schematic showing outcome of patients with B-cell precursor-acute lymphoblastic leukaemia with late bone marrow relapses in the ALLR3 trial as per allocated treatment
First complete remission refers to the time from completing front-line therapy. High minimal residual disease defined as ≥10−4 cells. Low minimal residual disease defined as <10−4 cells. SCT=stem-cell transplantation.
The Lancet Haematology 2019 6, e204-e216DOI: ( /S (19) )
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions

3. Figure 2
5-year Kaplan-Meier estimates of (A) progression-free survival and (B) overall survival in patients with high and low minimal residual disease
High minimal residual disease defined as ≥10−4 cells. Low minimal residual disease defined as <10−4 cells.
The Lancet Haematology 2019 6, e204-e216DOI: ( /S (19) )
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions

4. Figure 3
Frequency of somatic copy number alterations and mutations according to (A) cytogenetic risk groups and (B) minimal residual disease at timepoint 1
High minimal residual disease defined as ≥10−4 cells. Low minimal residual disease defined as <10−4 cells.
The Lancet Haematology 2019 6, e204-e216DOI: ( /S (19) )
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions